好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Implementation, Evaluation, and Use of Nonmydriatic Ocular Fundus Imaging in the Emergency Department: More Than Two Years of Prospective Consecutive Data
Neurohospitalist
P9 - Poster Session 9 (5:00 PM-6:00 PM)
2-011

To evaluate the sustainability of a table-top non-mydriatic ocular fundus camera combining 45°-true-color photographs and optical coherence tomography nerve/macula (NMFP-OCT) connected to our PACS/electronic health records in our general emergency department (ED).

We implemented ED-NMFP-OCT in 06/2023, 1,2 and have shown that NMFP-OCT performed by ED-staff on patients with vision complaints,3,4 headaches,5 neurologic disorders,6 hypertensive crisis,2 with remote interpretation of imaging by ophthalmologists: prevented diagnostic errors;8 accelerated triage/patient’s discharge;7 reduced in-person ophthalmology consultations;7,8 reduced burden/increased confidence among trainees.1,7,8

Prospective quality improvement project with systematic collection of data on consecutive patients who underwent ED-NMFP-OCT from implementation on 6/14/2023-09/23/2025.

3692 patients received NMFP-OCT (average, 4.4/day), with increasing rate of 0.126 NMFP-OCT/week.

Images ordered by ED-providers for vision complaints (2518/3692;68%), headache (732/3692;20%), other neurologic (309/3692;8%), hypertensive crisis (43/3692;1%), diabetes mellitus (79/3692;2%), other (11/3692;0.3%). Papilledema was ruled-out remotely in 789/981 (80%) patients with concern for intracranial hypertension, avoiding in-person consultations in 93.

NMFP-OCT (performed by ED-staff in 89%) was of quality good enough for interpretation in 3256/3692 (88%).

1406/3692 (38%) NMFP-OCT were abnormal: papilledema (245/1406;17.4%); other optic neuropathies (365/1406;26%); CRAO/BRAO (82/1406;5.8%); uveitis/retinitis (115/1406;8.2%), retinal detachment (176/1406;12.5%); vitreous hemorrhage (96/1406;6.8%); other vitreous+retinal abnormalities (230/1406;16.4%); incidental findings (97/1406;6.9%).

Camera/connections required rare (<1/month) routine maintenance lasting <3hrs, mostly from automated EHR/PACS updates. 

>2 years after implementation in our busy ED, daily NMFP-OCT continues to increase, with ED providers routinely ordering NMFP-OCT based on standard-of-care recommendations for fundus examination. Workflows were adapted to incorporate systematic NMFP-OCT for all patients with vision complaints prior to in-person ophthalmology consultations, and specifically-created protocols [“EyeSTroke Alerts”,9 “Papilledema Concern/Evaluation”].7,8

Our large prospective consecutive series confirms that ED-NMFP-OCT is sustainable, scalable, requiring minimal training for replicable use, efficacious for a wide variety of acute clinical presentations, continuing to improve patient care, patient outcomes, and trainee education, making its implementation desirable/likely feasible in other EDs.

Authors/Disclosures
Stuart J. Duffield
PRESENTER
Mr. Duffield has nothing to disclose.
Mung Yan Lin, MD Dr. Lin has nothing to disclose.
Jessica McHenry Ms. McHenry has nothing to disclose.
Kevin Yan, MD An immediate family member of Dr. Yan has received personal compensation in the range of $100,000-$499,999 for serving as a Pharmaceutical Reviewer with US Food and Drug Administration.
Nancy J. Newman, MD, FAAN (Emory University School of Medicine) Dr. Newman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for GenSight. Dr. Newman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Chiesi. Dr. Newman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Stoke. Dr. Newman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Newman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Phelcom. The institution of Dr. Newman has received research support from GenSight. Dr. Newman has received publishing royalties from a publication relating to health care. Dr. Newman has received publishing royalties from a publication relating to health care. Dr. Newman has received publishing royalties from a publication relating to health care.
Valerie Biousse, MD Dr. Biousse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gensights Biologic. Dr. Biousse has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Topcon. Dr. Biousse has received publishing royalties from a publication relating to health care. Dr. Biousse has received publishing royalties from a publication relating to health care.